Appendix 3B New issue announcement of 19 June 2018

Jul 27, 2018
Posted in: Investor updates

Home » Appendix 3B New issue announcement of 19 June 2018

Appendix 3B New issue announcement of 19 June 2018

Jul 27, 2018
Posted in: Investor updates

“Appendix 3B New issue announcement, application for quotation of additional securities and agreement” of 19 June, 2018 is posted.
View and download Appendix 3B New issue announcement, application for quotation of additional securities and agreement of 19 June, 2018.

Imagion Initiates Manufacturing of MagSense® Drug for Phase 2 Clinical Study on HER2+ Breast Cancer

February 19, 2025

MELBOURNE – Imagion Biosystems (Company) (ASX : IBX), a company dedicated to improving healthcare outcomes through the early detection of cancer, is pleased to announce

Corporate Update – IND for MagSense® HER2 Phase 2 Study Immediate Priority

November 14, 2024

Corporate Updates: $3M fundraising led by CPS Capital to be completed in early December Filing of IND for MagSense® HER2 Phase 2 Study Immediate Priority

Successful Placement of A$3M

October 10, 2024

Imagion Biosystems (ASX: IBX) (Company), is pleased to announce the Company has received $3 million of firm commitments through a highly successful capital raising. The

Transforming medical imaging for early disease detection

We’re on a mission to make cancer more detectable.

Appendix 3B New issue announcement of 19 June 2018

Appendix 3B New issue announcement of 19 June 2018

Related Articles

Imagion Initiates Manufacturing of MagSense® Drug for Phase 2 Clinical Study on HER2+ Breast Cancer

Corporate Update – IND for MagSense® HER2 Phase 2 Study Immediate Priority

Successful Placement of A$3M

Transforming medical imaging for early disease detection

About Imagion Biosystems

Contact us

Join our email list